NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) and certain of its officers and directors. The Class Action, filed in the United States District Court for the Central District of California and registered at 22-cv-07030, is on behalf of a class consisting of all persons and entities other than the defendants who purchased or otherwise acquired: (a ) Centessa American Depositary Shares (“ADSs”) pursuant to and/or traceable to the offering documents (defined below) issued in connection with the Company’s initial public offering on or about May 28, 2021 (the “IPO” or the “Offering”) became ; and/or (b) Centessa Securities between 28 May 2021 and 1 June 2022, both dates inclusive (the “Collection Period”). Plaintiff is pursuing claims against Defendants under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased or otherwise acquired Centessa ADSs pursuant to and/or traceable to the Company’s IPO offering documents and/or Centessa securities during the Class Period, you have until November 28, 2022 in court To apply for your appointment as lead plaintiff for the class. A copy of the complaint is available at To discuss this promotion, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Centessa is a clinical-stage pharmaceutical company that purports to discover, develop and deliver medicines to patients. The Company’s development pipeline includes Lixivaptan, a…

Continue to read on GlobeNewswire